anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention concerns the isolation, purification and characterisation of a protein having a novel enzymatic activity, i.e. an alpha-1,3-(3,6-anhydro)-D-galactosidase activity. This protein can be used for hydrolysing polysaccharides and oligosaccharides containing (non-sulfated) beta-carrabiose units, which may be present naturally (e.g. carrageenans extracted from red seaweeds of the Tichocarpus and Furcellaria genus) or introduced artificially by chemical or enzymatic desulfation (for example from kappa- and iota-carrageenans). The activity of this protein, demonstrated on oligo-carrageenans with a hybrid kappa/beta structure, makes it possible, for example, to produce the 3,6-anhydro-D-galactose monosaccharide and odd-numbered oligo-carrageenans of a defined size of the carrabiose series, i.e. having a D-galactose residue at the non-reducing end.
<P>PROBLEM TO BE SOLVED: To provide a transdermal delivery system capable of rapidly responding to the changeable request of a patient, rapidly delivering an additional amount of drugs, and allowing the patient to control the delivery of the additional drugs in response to the request.  <P>SOLUTION: The present invention is directed towards methods and apparatus using controlled heat to regulate transdermal and controlled release to rapidly deliver fentanyl, other analgesics, and other substances to the patient. The invention comprises a drug beneath a patient's skin in a drug depot. A heating component is placed near the drug depot site and generates heat in and near the drug depot site. A control component connected to the heating component is used to control the magnitude and duration of heat generated by the heating component.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Dose titration Saxenda (from 0.6 mg to 3.0 mg liraglutide once daily), should take place during the first 4 weeks after randomisation as described: Dose Escalation Schedule of Reference Product (Saxenda). All participants assigned to the open-labeled control group should aim to reach the final target dose of 3.0 mg liraglutide once daily.
PROBLEM TO BE SOLVED: To provide a system for eliminating subjectivity as much as possible for investigation contents by a care manager, providing objectivity and making illegal actions such as a false declaration impossible and to perform highly reliable authorization without troubling or burdening a care necessity application object person. SOLUTION: By using the storage medium of a large capacity such as an HD, a reference video image is brought and the quickness and sureness of an examination on the spot are improved. Since the actual operation state of the application object person is photographed with a digital camera and parallelly displayed with the reference video image, evaluation is more accurately decided. Since evaluation scoring is performed by a computer as well and turned to the object of the judgment of the care manager, erroneous evaluations are reduced. Also, the false declaration by the case manager is prevented. Linking with a care necessity authorization system head office is made possible through a LAN and the internet for respective cities, towns and villages.
Thrombin-antithrombin complex（TAT）, α2-plasmin inhibitor-plasmin complex（PIC）, tissue plasminogen activator-inhibitor complex（tPAI·C） and thrombomodulin（TM） can evaluate vascular endothelial damage, thrombin and plasminase activation, and have clinical significance in early diagnosis of DIC, thrombotic disease and monitoring of thrombolysis efficacy. However, whether these biomarkers can be used for early diagnosis of SIC is unclear.

In order to evaluate the diagnostic value of TAT, PIC, tPAI·C and TM in sepsis-induced coagulopathy(SIC), hospitalized patients with sepsis were prospectively included. Plasma TAT, PIC, tPAI·C,TM levels within 24 h after sepsis diagnosis were detected by MCL60 chemiluminescence analyzer. According to the SIC score (≥4), they were divided into SIC group and non-SIC group, and receiver operator characteristic（ROC） curve analysis was performed according to the biomarker test results. The area under the curve(AUC) was used to determine whether TAT, PIC, tPAI·C and TM could be used as biomarkers for SIC diagnosis. If AUC is between 0.7 and 0.9, this indicator has diagnostic value.
Patients undergo observation on study. Patients also undergo PET-CT and/or CT and undergo collection of blood and tissue samples throughout the study. Patients with subsequent progression within 12 months of CAR T-cell therapy may crossover to Arm III.
Inflammatory bowel disease (IBD) is a chronic disorder characterized by recurrent gastrointestinal inflammation, lacking a precise aetiology and definitive cure. The gut microbiome is vital in preventing and treating IBD due to its various physiological functions. In the interplay between the gut microbiome and human health, extracellular vesicles secreted by gut bacteria (BEVs) are key mediators. Herein, we explore the role of Roseburia intestinalis (R)-derived EVs (R-EVs) as potent anti-inflammatory mediators in treating dextran sulfate sodium-induced colitis. R was selected as an optimal BEV producer for IBD treatment through ANCOM analysis. R-EVs with a 76 nm diameter were isolated from R using a tangential flow filtration system. Orally administered R-EVs effectively accumulated in inflamed colonic tissues and increased the abundance of Bifidobacterium on microbial changes, inhibiting colonic inflammation and prompting intestinal recovery. Due to the presence of Ile-Pro-Ile in the vesicular structure, R-EVs reduced the DPP4 activity in inflamed colonic tissue and increased the active GLP-1, thereby downregulating the NFκB and STAT3 via the PI3K pathway. Our results shed light on the impact of BEVs on intestinal recovery and gut microbiome alteration in treating IBD.
INTRODUCTION: During the surge of the SARS-CoV-2 pandemic, studies revealed high complication and morbidity rates following surgical procedures in COVID-19 positive patients. Anesthetic and surgical societies swiftly developed strategies to mitigate these risks, including a recommended postponement of elective surgeries for a minimum of 7 weeks post-COVID infection. Nowadays, with a predominantly vaccinated population, it has become crucial to discern the influencing factors on post-COVID morbidity and mortality and a reevaluation of the existing recommendations pertaining to elective surgery.
METHODS: A single-center case-control study was conducted, including patients who underwent surgery between November 2021 and March 2022 and met the inclusion criteria. Eighty COVID-19 positive patients were matched 1:1 with 80 controls, each undergoing an identical intervention within a 2-week time frame. The primary outcome was 30-day postoperative mortality and secondary outcome postoperative complications (respiratory and thromboembolic).
RESULTS: At the time of surgery, 88.8% of patients in the case group and 92.5% in the control group had received at least one vaccine dose. Mortality and morbidity did not show a significant difference when comparing the case and control groups (7.5% vs 6.2%, p = 0.755; 11.3% vs 8.9%, p = 0.541 respectively). In the COVID-positive group, mortality was significantly associated with age over 70 years, ASA score over III, RCRI over 1, emergency procedures, and absence of thromboembolic prophylaxis.
CONCLUSIONS: In contrast to previously reported findings, we did not observe an increased morbi-mortality in patients with perioperative COVID-19 infection. It may not be necessary to delay elective interventions, except in cases with a high-risk.
Poly-ICLC molecules and methods for producing them, including certain specific molecular weight molecules having improved activity in certain applications. These molecules may be incorporated in pharmaceutically or veterinary acceptable excipients and carriers for a number of uses in humans, in domestic animals and in wild animals. Such uses include (but are not limited to) prophylaxis pre-exposure prophylaxis, treatment and/or inflammatory symptom attenuation of viral or microbial infections; immunomodulating, vaccine adjuvant, antiviral, and/or anti-inflammatory effects mediated through activation of the MDA5, TLR3 and other dsRNA dependent enzyme systems; antineoplastic effects either alone or when combined with therapeutic vaccine or other anticancer immunologic agents; preventive cancer vaccine adjuvant effects in patients at risk for cancer. The molecules may be of particular use against SARS-CoV-2 infection or a cytokine storm caused by a SARS-CoV-2 infection. While dosage may be adjusted depending on the specific target and the specific patient, the dose should be sufficient to activate the MDA5 and TLR3 enzyme systems in the patient. For humans the dose is between approximately 0.5 and 50 micrograms per kilogram body weight. The nature of the molecule does not demand any specific route of administration. Therefore, the route can be selected based on the specific target and the specific patient, and could include (but not be limited to) IM, SC, IT, IV or IN. Preferably, administration would comprise two or three repeated dose cycles spaced 24 to 96 hours apart. Depending on the target and the patient's response, dose cycles may be repeated 2 to 4 times per month.
PURPOSE:To ensure a practical hardening time and high initial strength by using powder obtd. by mixing alpha-calcium tert. phosphate with calcium prim. phosphate in a specified molar ratio of Ca to P as a base. CONSTITUTION:This hydraulic calcium phosphate cement compsn. is based on powder obtd. by mixing alpha-calcium tert. phosphate with calcium prim. phosphate in 1,400-1,497 molar ratio of Ca to P. This compsn. hardens within a practical time only by kneading with water, the hardened product has a small void volume, high initial strength and a great affinity for a living body and the pH can be kept nearly neutral.
Obesity and obstructive sleep apnea share a bidirectional relationship. While obesity is a major risk factor for OSA, OSA may contribute to weight gain. Recent evidence suggests that OSA treatment is associated with weight gain. The mechanisms involved in weight gain after OSA treatment are not known. The purpose of this study is to determine the mechanisms of weight gain during CPAP treatment for severe OSA leads. The investigators hypothesis is that CPAP leads to a decrease in energy expenditure and prevents the elimination of extracellular fluid that is accumulated during the day. In order to test this hypothesis, 20 patients with severe OSA aged between 50 and 80 years old, under regular treatment with CPAP, will be invited to participate. Using a cross-over design, the investigators will perform bioelectric impedance 5 times over 24 hours in order to assess the circadian effect of fluid accumulation in two different conditions: during CPAP treatment and 7 days after CPAP withdrawal. A full polysomnography will be performed during CPAP withdrawal to confirm severe OSA and during CPAP treatment to confirm adequate control of respiratory events. In addition, basal metabolic rate, hematocrit, serum BNP, urinary sodium, creatinine and osmolality will be determined in the morning during the CPAP and CPAP withdrawal periods.
Obesity in adult females impairs fertility by altering oxidative stress, DNA repair and chemical biotransformation. Whether prepubertal obesity results in similar ovarian impacts is under-explored. The objective of this study was to induce obesity in prepubertal female mice and assess puberty onset, follicle number, and abundance of oxidative stress, DNA repair and chemical biotransformation proteins basally and in response to 7,12-dimethylbenz(a)anthracene (DMBA) exposure. DMBA is a polycyclic aromatic hydrocarbon that has been shown to be ovotoxic. Lactating dams (C57BL6J) were fed either a normal rodent containing 3.5% kCal from fat (lean), or a high fat diet comprised of 60% kCal from fat, and 9% kCal from sucrose. The offspring were weaned onto the diet of their dam and exposed at postnatal day 35 to either corn oil or DMBA (1 mg/kg) for 7 d via intraperitoneal injection. Mice on the HFD had reduced (P < 0.05) age at puberty onset as measured by vaginal opening but DMBA did not impact puberty onset. Heart, spleen, kidney, uterus and ovary weight were increased (P < 0.05) by obesity and liver weight was increased (P < 0.05) by DMBA exposure in obese mice. Follicle number was largely unaffected by obesity or DMBA exposure, with the exception of primary follicle number, which were higher (P < 0.05) in lean DMBA exposed and obese control relative to lean control mice. There were also greater numbers (P < 0.05) of corpora lutea in obese relative to lean mice. In lean mice, DMBA exposure reduced (P < 0.05) the level of CYP2E1, EPHX1, GSTP1, BRCA1, and CAT but this DMBA-induced reduction was absent in obese mice. Basally, obesity reduced (P < 0.05) the abundance of CYP2E1, EPHX1, GSTP1, BRCA1, SOD1 and CAT. There was greater (P < 0.05) fibrotic staining in obese DMBA-exposed ovaries and PPP2CA was decreased (P < 0.05) in growing follicles by both obesity and DMBA exposure. Thus, prepubertal obesity alters the capacity of the ovary to respond to DNA damage, ovotoxicant exposure and oxidative stress.
The muscle stretching protocol described by Bressan (2008) will be followed, which consists of 8 consecutive weekly sessions, lasting 40-45 minutes. In dorsal decubitus or sitting, the triceps surae, hamstring, gluteal, paravertebral, latissimocondyloideus, pectoral, trapezius and respiratory muscles will be stretched. The exercises will be performed in a series of five repetitions for 30 seconds.
Your healthcare provider will take a medical and family history and examine you before prescribing oral contraceptives. The physical examination may be delayed to another time if you request it and your healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year. Be sure to inform your healthcare provider if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your healthcare provider, because this is a time to determine if there are early signs of side effects of oral contraceptive use. 

Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth control pills.
Parents of infants living in poverty are at significantly elevated risk of a host of detrimental outcomes, including the development of child behavior problems, neglect and abuse of children, child learning problems and parental substance abuse. Research has found that early interventions to improve parenting practices were effective to ameliorate these outcomes. Yet, there exist major obstacles to the effective delivery of mental health services, particularly in rural areas. The need of rural families for mental health services is reaching crisis proportions due to the dearth of trained professionals. In addition, the meteoric rise of Internet use has created a new avenue for people to communicate and share ideas. These two trends are helping fuel the demand for mental health services and on-line support.

Internet programs can be interactive and provide social support from peers and professionals. Through the use of recent advances in multimedia technology and software as well as the rise of computer networking via the Internet, there now exists an opportunity to provide such monitoring of outcomes and remote contact for rural locations. Prior developmental R34 research ("Infant Net") successfully adapted and pilot tested an existing empirically proven parenting program, for delivery via the Internet, enhanced with weekly professional contact. This research provided 40 mothers of infants 3.5 to 7 months (at enrollment) with a computer, computer camera, Internet connection, and technical training/support for 6 months to evaluate the digital translation. Mother-infant dyads were randomized to Experimental or Computer/Control conditions. Results found significant change with infant-behavioral and positive trends were demonstrated in parenting behaviors. Mothers rated the both computer program and interaction with coaches to be very high. These encouraging developmental research results provide a very good empirical base for a fully powered randomized control trial to test effectiveness.
A Randomized Clinical Trial was conducted at Sir Syed Sports Complex Sargodha, through convenience sampling technique on 52 patients which was allocated using random sampling through computerized generated number into Group A and Group B. Group A was treated with closed kinetic chain exercises. Group B was treated with abdominal contraction exercises for periscapular activation. These exercises were done in 3 sets with 10 repetitions. There was 3 sessions per week. Baseline measurement was taken on 1st day of evaluation and post treatment will be taken on 4th week. Data was analyzed during SPSS software version 25. After assessing normality of data by Shapiro-Wilk test, it was decided either parametric or non-parametric test was used within a group or between two groups.
To achieve maximum contraceptive effectiveness, Azurette (Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP) must be taken exactly as directed and at intervals not exceeding 24 hours. Azurette may be initiated using either a Sunday start or a Day 1 start.

NOTE: Each cycle pack dispenser is preprinted with the days of the week, starting with Sunday, to facilitate a Sunday start regimen. Six different "day label stickers" are provided with each cycle pack dispenser in order to accommodate a Day 1 start regimen. In this case, the patient should place the self-adhesive "day label sticker" that corresponds to her starting day over the preprinted days.

IMPORTANT: The possibility of ovulation and conception prior to initiation of use of Azurette should be considered.

The use of Azurette for contraception may be initiated 4 weeks postpartum in women who elect not to breast feed. When the tablets are administered during the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered (see CONTRAINDICATIONS and WARNINGS concerning thromboembolic disease. See also PRECAUTIONS for Nursing Mothers).

If the patient starts on Azurette postpartum, and has not yet had a period, she should be instructed to use another method of contraception until a dark blue tablet has been taken daily for 7 days.
1. Patients will receive docetaxel 40 mg/m2 IV every 2 weeks plus ADT. Docetaxel will be repeated on an outpatient basis and continued until disease progression, unacceptable toxicity, deterioration of clinical condition, patient refusal, or up to 6 to 8 cycles. ADT includes commercially available GNRH agonists such as goserelin, leuprolide and triptorelin, according to their market authorized approved label.
2. After the receipt of 6 to 8 cycles of first-line docetaxel plus ADT, patients with no evidence of disease progression (i.e., biochemical and clinical) will receive enzalutamide 160 mg PO daily. Enzalutamide will be continued until disease progression (i.e., development of mCRPC), unacceptable toxicity, deterioration of clinical condition, patient refusal.
1. A monoclonal antibody preparation for administration to a human having a concentration of 100mg/ml or greater obtained by a method comprising the steps of: (a) providing an antibody preparation; (b) ultrefiltering said antibody preparation after the step (a); and  (c) recirculating said filtrate after the step(b) at a circulation rate of less than 500 ml/min. 2. A preparation according to claim 1 wherein the solution at step a) is present at a concentration of less than 100mg/ml. 3. A preparation according to claim 1 wherein the preparation is substantially free from aggregate. 4. A preparation according to any of the preceding claims wherein the antibody is present at a concentration between 100 and 350mg/ml. 5. A preparation according to any of the preceding claims wherein the antibody is of the isotype IgG. 6. An antibody preparation according to any of the preceding claims wherein the antibody is a recombinant antibody. 7. An antibody preparation according to claim 6 wherein the antibody is an altered antibody. 8. An antibody preparation according to claim 7 wherein the antibody is a chimearic or a CDR-grafted antibody. 9. An antibody preparation according to claim 7 wherein the antibody binds to a T-celi or a cancer antigen. 10. A preparation according to any of the preceding claims wherein the pH of the preparation is different from the pH of the isoelectric point of the antibody. 11. A pharmaceutical formulation comprising the preparation according to any of the preceding claims. 12. Use of the preparation according to any of clams 1 to 10 in the manufacture of a medicament for the treatment of T-cell mediated disorders.
PROBLEM TO BE SOLVED: To prepare a hair tonic, excellent in promoting effects on hair production and having high safety. SOLUTION: This hair tonic comprises any of a hydroxyapatite powder, a suspension and, as necessary, a solution prepared by dissolving the powder in an organic acid or a powder, a suspension or an organic acid solution of a biological hard tissue containing the hydroxyapatite. The content of the hydroxyapatite is 0.01-10wt.% and the acid for dissolving the hydroxyapatite (e.g. citric acid) is blended in an amount of 0.01-1wt.% in a cosmetic for the hair of the head and the biological hard tissue component is blended in an amount of 0.01-50wt.% therein. The biological hard tissue is generically referred to as a hard part of a tissue in an organism containing calcium, further proteins and minerals such as animal bones, shells, crustacean exodermises, eggshells or corals and has excellent promoting effects on hair production.  This hair tonic does not cause damage to the hair and a cosmetic for the hair of the head having hair tonic actions together can be prepared. Thereby, this hair tonic is effectively used for baldness, alopecia, etc.
Cosmetic compositions are widely used to obtain certain benefits like e.g. anti-aging, skin lightening and moisturizing effect. These benefits are delivered by benefit agents (actives) like e.g. anti-oxidants, hyaluronic acid and resorcinol, pheynylethyl resorcinol and 4-alkyl substituted resorcinol. However, these actives have a certain shelf life beyond which they tend to degrade in terms of chemical activity and/or their color stability. The present invention discloses a novel process to prepare cosmetic compositions that improved color stability of resorcinol, pheynylethyl resorcinol and 4- alkyl substituted resorcinol and compositions comprising such actives when prepared as per said process.
The study is an open label study in which a comparative group of patients will be prospectively selected from a resource of clinical trial data, the Virtual International Stroke Trials Archive (VISTA), on the basis of similar eligibility criteria and match for principal prognostic variables available at trial entry. Data from patients will be transferred to VISTA in a real time or at most, weekly basis and comparative group patients will be prospectively matched throughout the recruitment period. The VISTA investigators will be blinded to treatment group when receiving data from BrainsGate. The VISTA investigators will match each recruited BrainsGate patient with 3 patients from the VISTA archive. The matching criteria will include age ± 4 years; baseline NIH score matched exactly, and side of infarct.

In addition, to the end of treatment visit, in which implanted patients will undergo a device removal procedure, two follow-up visits will be performed. The visits should be performed at 30±5, and at 90±5 post enrollment. Aggregate trial duration will be \~100 days per patient, and the overall study duration will be up to 18 months.